[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628603":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":33,"responsibleParty":131,"collaborators":133,"id":137,"slug":10,"hasResults":138,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":138,"sex":144,"minAge":145,"maxAge":10,"enrollmentInfo":146,"targetDuration":10,"studyType":149,"phases":10,"briefSummary":150,"conditions":151,"keywords":10,"overallStatus":155,"whyStopped":10,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":165},{"fullName":5,"class":6},"Fondazione Italiana Linfomi - ETS","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with DLBCL\u002FHGBL and PMBCL",null,"Patients with previous diagnosis of Diffuse Large B Cell Lymphoma or High-Grade B Cell Lymphoma (DLBCL\u002FHGBL), arising de novo or transformed from a previous indolent histotype (transformed Follicular Lymphoma or transformed Marginal Zone Lymphoma), Primary Mediastinal B Cell Lymphoma (PMBCL) scheduled to received CAR-T cell product according to Agenzia Italiana del Farmaco (AIFA) indications and technical data sheet of the drug",[13],"Other: Chimeric Antigen Receptor T-cells (CAR-T) therapy",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Chimeric Antigen Receptor T-cells (CAR-T) therapy","Patients will be treated with CAR-T cell product as per routine clinical practice.",[9],[20],{"name":21,"affiliation":22,"role":23},"Luca Castagna","A.O. Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Uffici Studi FIL","CONTACT","+390131033153","startup@filinf.it",{"name":26,"role":27,"phone":31,"phoneExt":10,"email":32},"+39 059 976 9911","gestionestudi@filinf.it",[34,48,60,72,83,95,107,119],{"facility":35,"status":10,"city":36,"state":10,"zip":10,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"SCDU Ematologia - AOU SS. Antonio e Biagio e Cesare Arrigo di Alessandria","Alessandria","Italy",{"type":39,"coordinates":40},"Point",[41,42],8.61007,44.90924,{"lat":42,"lon":41},[45],{"name":46,"role":27,"phone":10,"phoneExt":10,"email":47},"Manuela Zanni","manuela.zanni@ospedale.al.it",{"facility":49,"status":10,"city":50,"state":10,"zip":10,"country":37,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"Clinica di Ematologia, AOU Ospedali Riuniti","Ancona",{"type":39,"coordinates":52},[53,54],13.5103,43.60717,{"lat":54,"lon":53},[57],{"name":58,"role":27,"phone":10,"phoneExt":10,"email":59},"Guido Gini","guido.gini@ospedaliriuniti.marche.it",{"facility":61,"status":10,"city":62,"state":10,"zip":10,"country":37,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"USD-TMO Adulti - ASST Spedali Civili di Brescia","Brescia",{"type":39,"coordinates":64},[65,66],10.21472,45.53558,{"lat":66,"lon":65},[69],{"name":70,"role":27,"phone":10,"phoneExt":10,"email":71},"Michele Malagola","michele.malagola@unibs.it",{"facility":73,"status":10,"city":74,"state":10,"zip":10,"country":37,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Divisione di Ematologia - A.O. Ospedali Riuniti Villa Sofia-Cervello","Palermo",{"type":39,"coordinates":76},[77,78],13.3636,38.1166,{"lat":78,"lon":77},[81],{"name":21,"role":27,"phone":10,"phoneExt":10,"email":82},"l.castagna@villasofia.it",{"facility":84,"status":10,"city":85,"state":10,"zip":10,"country":37,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"Ematologia - Grande Ospedale Metropolitano Bianchi Melacrino Morelli","Reggio Calabria",{"type":39,"coordinates":87},[88,89],15.66129,38.11047,{"lat":89,"lon":88},[92],{"name":93,"role":27,"phone":10,"phoneExt":10,"email":94},"Martino Massimo","dr.massimomartino@gmail.com",{"facility":96,"status":10,"city":97,"state":10,"zip":10,"country":37,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Ematologia - Università Cattolica S. Cuore","Roma",{"type":39,"coordinates":99},[100,101],11.10642,44.99364,{"lat":101,"lon":100},[104],{"name":105,"role":27,"phone":10,"phoneExt":10,"email":106},"Simona Sica","simona.sica@unicatt.it",{"facility":108,"status":10,"city":109,"state":10,"zip":10,"country":37,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"SC Ematologia - Ospedale \"S.G. Moscati\"","Taranto",{"type":39,"coordinates":111},[112,113],17.24707,40.46438,{"lat":113,"lon":112},[116],{"name":117,"role":27,"phone":10,"phoneExt":10,"email":118},"Claudia Ingrosso","claudia.ingrosso@asl.taranto.it",{"facility":120,"status":10,"city":121,"state":10,"zip":10,"country":37,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"SOC Clinica Ematologica - Azienda Sanitaria Universitaria Friuli Centrale (ASU FC)","Udine",{"type":39,"coordinates":123},[124,125],13.23715,46.0693,{"lat":125,"lon":124},[128],{"name":129,"role":27,"phone":10,"phoneExt":10,"email":130},"Jacopo Olivieri","jacopo.olivieri@asufc.sanita.fvg.it",{"type":132,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[134],{"name":135,"class":136},"Fondazione Lorenzo Farinelli Onlus","UNKNOWN","100628603",false,"NCT07463781","Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy","Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy: a Multicenter Observational Prospective Study","NEURO_CAR-T","Inclusion Criteria:\n\n* Patients with previous diagnosis of Diffuse Large B Cell Lymphoma or High- Grade B Cell Lymphoma (DLBCL\u002FHGBL), arising de novo or transformed from a previous indolent histotype (transformed Follicular Lymphoma or transformed Marginal Zone Lymphoma), Primary Mediastinal B Cell Lymphoma (PMBCL).\n* Patients undergoing CD19-targeted CAR-T cell salvage therapy for relapsed\u002Frefractory disease according to AIFA inclusion criteria.\n* Age over 18-years-old at the time of lymphoma diagnosis.\n\nExclusion Criteria:\n\n* Patient with histological diagnosis of mantle cell lymphoma (MCL) or acute lymphoblastic leukemia (ALL)\n* Patients with CNS disease localization.\n* Patients that received brain\u002Fneuroaxis radiotherapy.\n* Pre-existing severe psychiatric or neurologic comorbidities influencing neurocognitive assessment.","ALL","18 Years",{"count":147,"type":148},100,"ESTIMATED","OBSERVATIONAL","This is an observational, multicenter, prospective cohort study including patients treated with CAR-T in Italian centers. Patients eligible for enrollment in the study will be consecutively included in Italian FIL centers. A longitudinal survey will be carried out by collecting patients' data before starting CAR-T (T0) and after 6 (T1), 12 (T2) and 24 (T3) months after CAR-T infusion.",[152,153,154],"Diffuse Large B Cell Lymphoma (DLBCL)","High Grade B Cell Lymphoma","Primary Mediastinal B-cell Lymphoma (PMBCL)","NOT_YET_RECRUITING","2026-03-11",{"date":158,"type":159},"2026-03-13","ACTUAL",{"date":161,"type":148},"2026-05",{"date":163,"type":148},"2029-05",{"name":5,"class":6},8]